Milbemycin Oxime, Lufenuron

Verify with FDA CVM →

6,743 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
6,743
Total Reports
63
Deaths Reported
90.0%
Death Rate

Active Ingredients

Milbemycin Oxime, Lufenuron

Administration Routes

OralUnknownTopicalIntrauterine

Species Affected

Dog 6,527
Unknown 196
Cat 10
Human 9
Goat 1

Most Affected Breeds

Crossbred Canine/dog 942
Retriever - Labrador 903
Dog (unknown) 355
Shepherd Dog - German 329
Retriever - Golden 322
Beagle 209
Unknown 206
Terrier - Yorkshire 150
Chihuahua 142
Boxer (German Boxer) 134

Most Reported Reactions

INEFFECTIVE, HEARTWORM LARVAE 1,493
Lack of efficacy (endoparasite) - hookworm 1,406
Vomiting 1,011
INEFFECTIVE, ASCARIDS NOS 838
Diarrhoea 583
Lethargy (see also Central nervous system depression in 'Neurological') 428
Lack of efficacy (endoparasite) - whipworm 424
Lack of efficacy - NOS 348
Lack of efficacy (ectoparasite) - flea 300
INEFFECTIVE, HOOKS 220
Underdose 184
Overdose 181

Outcome Breakdown

Outcome Unknown
4,561 (69.6%)
Recovered/Normal
1,798 (27.4%)
Ongoing
100 (1.5%)
Died
32 (0.5%)
Euthanized
31 (0.5%)
Recovered with Sequela
29 (0.4%)

Data Summary

Metric Value
Total adverse event reports 6,743
Reports involving death 63
Case-fatality rate (reported events) 90.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin Oxime, Lufenuron Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 6,743 adverse event reports referencing Milbemycin Oxime, Lufenuron, including 63 reports in which the animal died — a 90.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin Oxime, Lufenuron. Reported administration routes include Oral, Unknown, Topical, Intrauterine. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin Oxime, Lufenuron reports are Dog (6,527 reports), Unknown (196 reports), Cat (10 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (942), Retriever - Labrador (903), Dog (unknown) (355) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin Oxime, Lufenuron are INEFFECTIVE, HEARTWORM LARVAE (1,493), Lack of efficacy (endoparasite) - hookworm (1,406), Vomiting (1,011), INEFFECTIVE, ASCARIDS NOS (838). Of the 6,551 reports with a coded outcome, Outcome Unknown is the leading category at 69.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin Oxime, Lufenuron.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial